SpectraCure Overview

  • Founded
  • 2003

Founded
  • Status
  • Public

  • Employees
  • 17

Employees
  • Stock Symbol
  • SPEC

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $0.35

  • (As of Tuesday Closing)

SpectraCure General Information

Description

SpectraCure AB develops treatment planning and laser light dose management for cancer treatment. The Company has developed its software IDOSE, and medical laser devices for the treatment.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Stock Exchange
STO
Primary Office
  • Gasverksgatan 1
  • 222 29 Lund
  • Sweden
+46 046-16 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SpectraCure Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.35 $0.35 $0.28 - $1.20 $34.4M 97.1M 161K -$0.03

SpectraCure Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 61,252 48,192 181,329 244,466
Revenue 0 0 0 0
EBITDA (2,532) (2,405) (1,414) (1,211)
Net Income (2,710) (2,718) (1,671) (1,447)
Total Assets 17,144 21,052 25,665 10,716
Total Debt 382 542 654 718
Public Fundamental Data provided by Morningstar, Inc. disclaimer

SpectraCure Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore SpectraCure‘s full profile, request access.

Request a free trial

SpectraCure Patents

SpectraCure Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3915463-A4 System and method for distributing radiation for diagnostics Pending 29-May-2020 0000000000
EP-3915463-A1 System and method for distributing radiation for diagnostics Pending 29-May-2020 0000000000
CA-3135863-A1 System and method for determining light attenuation at optical members inserted in tissue Pending 04-Apr-2019 0000000000
EP-3946573-A1 System and method for determining light attenuation at optical members inserted in tissue Active 04-Apr-2019 0000000000
US-11331512-B2 System and method for determining light attenuation at optical members inserted in tissue Active 04-Apr-2019 A61N5/0601 0
To view SpectraCure’s complete patent history, request access »

SpectraCure Executive Team (7)

Name Title Board Seat Contact Info
Johan Folkunger Chief Executive Officer
Henrik Ljung Chief Financial Officer, Finance
Johannes Swartling Ph.D Chief Technology Officer & Technical Manager
Kristina Hallström Chief Marketing Officer & Chief Commercial Officer
Johan Ingemansson Business Development Manager & Head, Business Development
You’re viewing 5 of 7 executive team members. Get the full list »

SpectraCure Board Members (7)

Name Representing Role Since
Jesper Freij SpectraCure Board Member 000 0000
Katarina Svanberg Ph.D Self Board Member 000 0000
Masoud Khayyami Ph.D Self Board Member 000 0000
You’re viewing 3 of 7 board members. Get the full list »

SpectraCure Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SpectraCure Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000000 07-Apr-2008 000000000 Buildings and Property
To view SpectraCure’s complete investments history, request access »